Program
JZP441
A development code.
Its studies are mostly in Narcolepsy, led by Jazz Pharmaceuticals.
Furthest: phase 1, since Nov 28, 20223 company-led studies, 0 open or running
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Jazz Pharmaceuticals | 30 open or running | phase 1since Nov 28, 2022 | Nov 28, 2022 | none ahead |
Also a collaborator on its studies: jazz-pharmaceuticals-ireland-limited.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Nov 28, 2022First study: phase 1 study in Healthy ParticipantsFirst studyNCT05651152 · 105 enrolled · United States
- Jan 31, 2023Phase 1 study in Healthy ParticipantsNCT05720494 · 24 enrolled · United States
- Apr 29, 2025Phase 1 study in NarcolepsyNCT06961266 · 6 enrolled · United States
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06961266Narcolepsy · United States | 1 | Terminated | Jan 29, 2026 | 6 |
| NCT05720494Healthy Participants · United States | 1 | Completed | Sep 29, 2023 | 24 |
| NCT05651152Healthy Participants · United States | 1 | Completed | Nov 15, 2023 | 105 |
How it is read
Names in the registry
- “JZP441”, 3 entries
Codes read as this program: JZP441.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.